Recurrent Generic Chemotherapy Shortages Reveal Persistent Supply Chain Fragilities Despite Prior Warnings

{"Manufacturing quality failures at contract plants, combined with low generic margins, triggered the current wave affecting cisplatin, carboplatin, and ifosfamide. Baxter’s German facility received an FDA warning letter after sterility lapses, mirroring the 2023 carboplatin-cisplatin shortage that lasted months. The Times reporting, corroborated by FDA shortage listings, shows how single-source dependencies amplify disruptions when quality issues halt production.","Economic analyses in JAMA Internal Medicine (2024) demonstrate that sterile injectable generics priced below $20 per dose lack incentives for redundant capacity or quality upgrades. Hospitals now space infusions and prioritize younger patients, practices documented in prior observational studies but not systematically tracked for survival impact. This pattern reflects structural underinvestment rather than isolated events.","Federal responses remain limited to import waivers and manufacturer coordination, measures attempted after the 2023 shortage without statutory changes to stockpiling or price floors. Premier data and clinician interviews indicate rationing is already occurring regionally, yet no national registry exists to quantify missed doses or outcome shifts.","Next steps hinge on whether Congress enacts incentives for domestic sterile manufacturing redundancy or authorizes strategic reserves, actions proposed but not funded in the 2024-2025 appropriations cycle."}